ROIV Stock Card: Scores, Risk & Setup | Stoxcraft

Roivant Sciences Ltd.

Health

Performance

4.4

Risk

Sell

Buy

Curious about the Scores? Learn more.

Roivant Sciences Ltd. stock rating and score history

All changes in ratings, performance and outlook tracked over time.

03.09.2026

Losing steam. Solid pieces remain, but cracks are showing.

29.08.2026

Risk creeping up. Stability not bulletproof anymore.

01.07.2026

Danger zone. Balance sheet’s flashing red across the board.

12.10.2025

Outperforming hard. Momentum locked in.

ROIV

Roivant Sciences Ltd.

34.41

+0.67%

4.4

Sell

Buy

© Stoxcraft

Roivant Sciences Ltd.

Roivant Sciences Ltd. stock price, chart patterns and momentum

Recent price movements, trend behaviour and momentum signals based on real-time market data.

What does Roivant Sciences Ltd. do? Business model and key facts

Get the full picture of Roivant Sciences Ltd.: what it builds, where it operates, and how it makes money.

Roivant Sciences Ltd. Profile

Sector: Healthcare

Industry: Biotechnology

Employees (FY): 721

Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.

Company facts

Matthew Gline

CEO

721

Employees worldwide

Performance

173.31%

Last 12 months

245.48%

Last 5 years

Growth

$8.26M

Revenue year

$-397,907,000

Net income

Valuation

$25.07B

Market Cap

-64.42

Price/Earnings Ratio

Stocks related to Roivant Sciences Ltd.

Selected based on industry alignment and relative market positioning.

INCY

Incyte Corporation

128.00

-0.64%

3.6

Sell

Buy

© Stoxcraft

Incyte Corporation

BNTX

BioNTech SE

102.88

-0.90%

5.1

Sell

Buy

© Stoxcraft

BioNTech SE

INSM

Insmed Incorporated

126.68

+0.04%

7.9

Sell

Buy

© Stoxcraft

Insmed Incorporated

UTHR

United Therapeutics Corporation

490.24

-0.36%

3.4

Sell

Buy

© Stoxcraft

United Therapeutics Corporation

GMAB

Genmab A/S

34.41

+0.57%

3.0

Sell

Buy

© Stoxcraft

Genmab A/S

Events and news impacting Roivant Sciences Ltd. stock

Earnings, coporate decisions and industry developments that can affect the share price.

Toroshi stands before a performance leaderboard dominated by gold and copper stocks with perfect 10.0 scores, while cybersecurity, biotech, and asset management names also rank near the top.

These 10 stocks have the highest performance scores right now

5 min 57 sec read

These 10 stocks have the highest performance scores right now

Copper and gold miners are dominating this week's Performance Score rankings. See which 10 stocks lead the pack.

HypeMeter-img

Slightly Bullish

Moderna, Tempus AI and Adecoagro stocks surge in Triple Boost race

3 stock risers this week: Moderna, Tempus AI, and Adecoagro soar

4 min 7 sec read

3 stock risers this week: Moderna, Tempus AI, and Adecoagro soar

A cancer-drug breakthrough sent Moderna up 124% and Tempus AI soaring this week. Adecoagro rounds out the trio with a record EBITDA quarter.

HypeMeter-img

Toroshi watches a stable green Moderna cancer-vaccine science core inside an overheating red market chamber, showing a real biotech breakthrough amid extreme stock-price volatility.

Moderna (MRNA) gives back 20% of its historic cancer-vaccine rally

4 min 1 sec read

Moderna (MRNA) gives back 20% of its historic cancer-vaccine rally

Moderna soared 177% on cancer vaccine data, then gave back over 20% the next day. The Health Score never believed the story.

HypeMeter-img

Slightly Bullish

Toroshi inspects an overheated ABCL biotech engine glowing red at extreme momentum while weaker health warnings flash beside calmer ADPT and RCUS systems.

ABCL stock forecast: up 68% and overbought, but the score says sell

5 min 41 sec read

ABCL stock forecast: up 68% and overbought, but the score says sell

ABCL is up nearly 70% in a month and deep in overbought territory. Its Health Score of 1.8 tells a very different story than the chart.

HypeMeter-img

Stock Market Winners of the Week: ABCL, HTZ &amp; NBIS

Riser of the week: ABCL, HTZ and NBIS surge on earnings

5 min 5 sec read

Riser of the week: ABCL, HTZ and NBIS surge on earnings

A drug win, a short squeeze and an AI earnings beat sent ABCL, HTZ and NBIS soaring this week. Their Stoxcraft scores tell three different stories.

HypeMeter-img

Toroshi scanning UNH healthcare mech before earnings — Stoxcraft score analysis

UnitedHealth (UNH) nears its 52-week high ahead of its earnings date. The score isn't buying it.

5 min 18 sec read

UnitedHealth (UNH) nears its 52-week high ahead of its earnings date. The score isn't buying it.

UnitedHealth (UNH) sits 2% below its 52-week high. The stock is up 41% in a year. Its own scorecard is not nearly as impressed.

HypeMeter-img

Slightly Bullish

Toroshi presents five stock fighters labeled ACMR, MXL, HUM, BJRI, and SN in a futuristic low-poly arena.

June's 5 strongest-trending stocks: the fundamentals aren't equal

5 min 25 sec read

June's 5 strongest-trending stocks: the fundamentals aren't equal

Humana just hit a 52-week high. Analysts keep raising price targets. Its performance score still says something's off.

HypeMeter-img

Slightly Bullish

Top Healthcare Stocks in 2026: UTHR, KRYS, and LLY

The three healthcare stocks with the strongest fundamentals in 2026

5 min 51 sec read

The three healthcare stocks with the strongest fundamentals in 2026

One healthcare stock just hit a score no other company has ever reached. The fundamentals are that clean. Here are the three names leading the sector right now.

HypeMeter-img

Slightly Bullish

Stoxcraft 2026 health score screen shows only 8% of stocks reaching top-tier fundamentals

Health score distribution 2026: what 3,884 stocks reveal about fundamental quality

2 min 31 sec read

Health score distribution 2026: what 3,884 stocks reveal about fundamental quality

We scored 3,884 stocks on fundamental health. Most are average. Only 8% clear the top threshold. If you've ever wondered which sectors dominate on fundamentals in 2026, the distribution answers it.

HypeMeter-img

Low Risk Stocks 2026: Only 5 Survived the Stoxcraft Screener

Low risk stocks 2026: Stoxcraft health score screener

5 min 58 sec read

Low risk stocks 2026: Stoxcraft health score screener

Most "low risk" stocks are just slow. We screened 3,487 stocks for the combination of low volatility AND strong fundamentals. Only 5 made the cut. These are the names the screener found.

HypeMeter-img

Why is Eli Lilly down 23% while Mounjaro keeps growing?

Why is Eli Lilly down 23% while Mounjaro keeps growing?

Company Spotlight

4 min 12 sec read

Why is Eli Lilly down 23% while Mounjaro keeps growing?

Lilly grew revenue 43% last quarter. Its stock is down 23% since January. Today's Q1 2026 earnings decide which story the market believes.

HypeMeter-img

A futuristic low-poly bull in a high-tech lab outfit scans a glowing DNA strand, highlighting how deeper analysis can reveal hidden signals and overlooked value in biotech data like United Therapeutics.

United Therapeutics stock: what the data says about UTHR

8 min 45 sec read

United Therapeutics stock: what the data says about UTHR

United Therapeutics carries a Health Score of 99 out of 100 and a net margin above 41%. Up 66% in 12 months. Here's what the fundamentals show.

HypeMeter-img

Slightly Bullish

A focused bull analyzes a glowing DNA structure inside a futuristic lab, symbolizing the complexity behind biotech innovation. While most investors see uncertainty, the real value often lies in understanding what others overlook.

United Therapeutics (UTHR) is the most undervalued large-cap biotech right now

Tech & Innovation

6 min 20 sec read

United Therapeutics (UTHR) is the most undervalued large-cap biotech right now

United Therapeutics just posted a fourth straight year of record revenue. It's debt-free, generating $4.7B in cash, and trades at half the P/E of its peers. The market still hasn't figured this one out.

HypeMeter-img

Low-poly, gaming-inspired hospital scene featuring the Stoxcraft bull as a doctor holding a large GLP-1 injector while consulting a patient, symbolizing Hims &amp; Hers expanding into weight-loss treatments.

HIMS stock up 57%: what the Novo deal really means

8 min 46 sec read

HIMS stock up 57%: what the Novo deal really means

Hims & Hers just had its best week on record. Novo Nordisk dropped the lawsuit. Now HIMS sells Ozempic and Wegovy at $149–$299/month. This changes everything.

HypeMeter-img

Stylized low-poly bull real estate investor standing in a commercial property district, looking at a glowing “667 Streak” sign symbolizing Realty Income’s record of consecutive monthly dividend payments.

The dividend stock that hasn't missed a payment in 30 years

6 min 41 sec read

The dividend stock that hasn't missed a payment in 30 years

Realty Income has paid investors every month for 30 years straight. That streak survived 2008 and COVID without a single miss. The stock's Stoxcraft scores tell a more complicated story.

HypeMeter-img

Roivant Sciences Ltd. fundamentals and technical analysis

Financial fundamentals and technicals signals combined to access stability, momentum and market direction.